Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT-ONO1
- Development stage
- Preclinical
- Lead developer
- Fate Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
FT-ONO1 is an investigational drug candidate derived from induced pluripotent stem cell (iPSC) technology and engineered as a T cell immunotherapy. It is being developed jointly by Fate Therapeutics and Ono Pharmaceutical, primarily for the treatment of hematologic malignancies. FT-ONO1 utilizes CAR-targeted, TCR-null CD8αβ+ T cells generated from iPSCs. The approach aims to provide off-the-shelf, allogeneic cell therapy targeting cancer cells, leveraging the advantages of iPSC-derived immune effector cells for scalable and consistent manufacturing. The mechanism of action is based on engineered T cells targeting specific tumor antigens via Chimeric Antigen Receptor (CAR) technology, and the use of TCR-null cells aims to reduce the risk of graft-versus-host disease in recipients[1][15].
- Other names
- FT-ONO1FT-ONO-1FT-ONO 1
02
Targets
CXCR2 (C-X-C Motif Chemokine Receptor 2)TGFB (GARP–latent transforming growth factor beta 1 complex)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on FT-ONO1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT-ONO1.